Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune reconstitution after bone-marrow transplantation.

M Symann1, A Bosly, C Gisselbrecht

  • 1Oncology Unit (Oncology and Experimental Hematology Laboratory), Catholic University of Louvain, Brussels, Belgium.

Cancer Treatment Reviews
|June 1, 1989
PubMed
Summary

Bone marrow transplant (BMT) recipients experience immune deficiency, particularly in T-cell function recovery, which may be improved with interleukin-2 (IL-2) therapy. This research explores IL-2

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.

Bone marrow transplantation·2016
Same author

Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

Bone marrow transplantation·2015
Same author

Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats.

Advances in hematology·2011
Same author

Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.

Heart, lung & circulation·2010

Area of Science:

  • Immunology
  • Transplantation Medicine
  • Cellular Biology

Background:

  • Allogeneic and autologous bone marrow transplantation (BMT) recipients exhibit significant T and B lymphocyte immune deficiency.
  • Quantitative immune recovery is observed within 3-4 months, but qualitative immune functions, like T-cell proliferation, recover slowly (over 1 year).
  • A defect in interleukin-2 (IL-2) production is noted post-BMT, despite T-cells being TAC+ (indicating potential responsiveness).

Purpose of the Study:

  • To investigate the potential of recombinant interleukin-2 (rIL-2) administration to normalize T-cell proliferation defects post-BMT.
  • To assess the impact of rIL-2 on immunological reconstitution in autologous bone marrow transplantation (ABMT) patients.
  • To evaluate rIL-2 as a consolidative immunotherapy in ABMT.

Main Methods:

Related Experiment Videos

  • Analysis of T-cell proliferation and TAC+ status post-BMT.
  • Assessment of Natural Killer (NK) and Lymphokine-Activated Killer (LAK) cell activities early post-BMT.
  • Clinical investigation of rIL-2 administration in ABMT patients.

Main Results:

  • T-cell proliferation is impaired post-BMT, with delayed recovery beyond one year.
  • A deficiency in IL-2 producing cells is identified, though PHA-stimulated T cells remain TAC+.
  • NK and LAK activities normalize early after BMT.

Conclusions:

  • The impaired T-cell proliferation post-BMT may be linked to a defect in IL-2 production.
  • In vitro addition of IL-2 shows potential to correct T-cell proliferation defects.
  • Clinical trials are underway to evaluate rIL-2 for immunological reconstitution and as immunotherapy in ABMT patients.